Zhendong Chen

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Zhenggang Ren, Jianming Xu, Yuxian Bai et al. · The Lancet Oncology · 2021 · 1.1K citations

Medicine, Oncology, Pharmacology +13

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 488 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Radiomic signature as a diagnostic factor for histologic subtype classification of non-small cell lung cancer

Xinzhong Zhu, Di Dong, Zhendong Chen et al. · European Radiology · 2018 · 215 citations

Medicine, Oncology, Radiology +17

Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial

Shukui Qin, Zhendong Chen, Weijia Fang et al. · Journal of Clinical Oncology · 2022 · 189 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial

Feng Wang, Shukui Qin, Xinchen Sun et al. · Journal of Hematology & Oncology · 2020 · 137 citations · Full text

Medicine, Oncology, Pharmacology +17